Hims & Hers Health, Inc. (NYSE: HIMS) is back in the market spotlight. As of early December 5, 2025, the telehealth company’s stock is trading around $40 per share, up sharply from recent lows but still far below its 52‑week high near $73.
In the last few weeks, Hims & Hers has:
- Reported another quarter of nearly 50% revenue growth
- Launched a nationwide Labs testing platform
- Announced a $250 million share repurchase program
- Entered Canada via the acquisition of weight‑loss platform Livewell
- Agreed to acquire YourBio Health, a specialist in painless blood sampling
- Hired former senior FDA official Deb Autor as its first chief policy officer
- Received a new “Strong Buy” rating from Leerink Partners
All of that is unfolding against a backdrop of regulatory scrutiny on GLP‑1 weight‑loss drugs, elevated short interest and a valuation that some see as stretched and others call undervalued.
Below is a breakdown of where HIMS stock stands today, what the latest news means, and how Wall Street is framing the outlook.
HIMS stock today: price, volatility and technical picture
According to StockAnalysis, Hims & Hers closed at $40.02 on December 4, 2025, up almost 8% on the day, with pre‑market quotes on December 5 edging slightly higher.
Key snapshot metrics:
- Share price: ~$40
- Market cap: ≈ $9.1 billion
- TTM revenue: ≈ $2.2 billion
- EPS (TTM): $0.54
- P/E ratio: ~74.5x
- Forward P/E: ~68x
- 52‑week range: $23.97 – $72.98
- Beta: ~2.4 (high volatility)
A Benzinga technical rundown on December 4 noted that HIMS is trading slightly above its 20‑day simple moving average, but remains below its 50‑, 100‑ and 200‑day moving averages, which still paints a broadly bearish trend. The piece flagged $34 as a key support level and $40 as near‑term resistance, with the RSI around 41, in neutral territory.
On the sentiment side, HIMS regularly appears on lists of the most shorted U.S. stocks, underlining how polarizing the name has become.
Q3 2025: explosive growth, tighter guidance
Hims & Hers’ latest earnings update, for the quarter ended September 30, 2025, showed another period of extremely fast growth.
From the company’s Q3 2025 results:
- Revenue: $598.98 million, up 49% year‑over‑year, and above analyst estimates (~$580 million)
- Online revenue: $589.1 million, up 50% YoY
- Subscribers: 2.47 million, up 21% YoY
- Monthly online revenue per subscriber:$80, up 19%
- Gross margin:74%, down from 79% a year ago
- Net income:$15.8 million (down vs. prior year which benefited from a large tax valuation allowance release)
- Adjusted EBITDA:$78.4 million, up 53% YoY
- Operating cash flow (Q3):$148.7 million
- Free cash flow (Q3):$79.4 million
For Q4 2025, management guided to:
- Revenue of $605–625 million
- Adjusted EBITDA of $55–65 million (9–10% margin)
For the full year 2025, Hims & Hers now expects:
- Revenue of $2.335–2.355 billion
- Adjusted EBITDA of $307–317 million (≈13% margin)
Reuters also highlighted that management is still targeting $6.5 billion in revenue by 2030, and reiterated a goal of generating about $725 million in GLP‑1 weight‑loss revenue in 2026.
The quarter beat expectations on revenue but missed EPS estimates (reported $0.06 vs consensus $0.09), which has made some investors more cautious even as topline growth remains near 50%.
Strategic push: Labs, YourBio and a Canadian beachhead
The most important story around Hims & Hers right now isn’t one single quarter, but a cluster of strategic moves aimed at turning the platform into a broader, data‑rich health system.
“Labs” – turning diagnostics into a subscription product
In mid‑November, Hims & Hers launched Labs, a subscription diagnostics hub that lets customers track dozens of health markers and receive doctor‑developed action plans.
Key details from company and media coverage:
- Labs is being rolled out in partnership with Quest Diagnostics, giving access to blood draws at over a thousand locations in the U.S.
- There are two annual subscription tiers:
- A base plan (around $199/year) with one blood draw and roughly 50 biomarker tests
- An advanced plan (around $499/year) with two blood draws and about 120 biomarkers across ~10 health categories
- Results are delivered inside the Hims & Hers platform, with physicians able to recommend lifestyle changes, supplements or prescriptions where clinically appropriate.
The intent is clear: use diagnostics to deepen customer relationships, boost average revenue per user, and feed richer data into the care model.
YourBio Health: painless blood sampling
On December 3, Hims & Hers announced a definitive agreement to acquire YourBio Health, a Boston‑based company whose TAP® device uses bladeless microneedles “thinner than an eyelash” to collect capillary blood samples in seconds with minimal discomfort.investors.hims.com
- The deal is all cash, funded from Hims & Hers’ balance sheet, and expected to close in early 2026, subject to approvals.
- YourBio’s HALO™ technology underpins the TAP device and is protected by a large patent portfolio.
- YourBio’s CEO and Chief Scientific Officer will join Hims & Hers to help scale the technology.
Strategically, this slots directly into Labs and longer‑term plans for at‑home and low‑friction diagnostics, reinforcing the platform’s move into preventive and longitudinal care.
Canada expansion via Livewell acquisition
On December 4, Hims & Hers announced its official entry into Canada after completing the purchase of Livewell, a Canadian digital health platform focused on weight loss.
From the company’s release:
- Livewell provides weight‑loss treatment via licensed providers across Canada and will be integrated into the Hims & Hers ecosystem.
- The deal is all cash, again funded from the company’s balance sheet.
- Hims & Hers plans to accelerate the launch of its comprehensive weight‑loss program in Canada in 2026, timed with the expected arrival of generic semaglutide there.
- Nearly two‑thirds of Canadian adults are overweight or living with obesity, and access to GLP‑1‑based therapies remains limited by cost and system constraints.
Benzinga noted that the Livewell deal leaves Hims & Hers operating across the U.S., Europe and now Canada, with management explicitly framing the move as a response to the obesity crisis and a step toward building a global consumer health brand.
Capital allocation: $250M buyback and a beefed‑up policy team
New $250 million share repurchase program
On November 17, Hims & Hers’ board authorized a new $250 million share repurchase program running over the next three years.
Key points:
- The authorization follows a prior $100 million buyback program launched in July 2024, which has now been fully utilized.
- Between October 1 and November 7, 2025, the company repurchased 1.33 million shares for about $55.5 million as part of that earlier program.
- CEO Andrew Dudum said management sees moments when the market price “does not fully reflect” intrinsic value and intends to use buybacks opportunistically, funded by a strong balance sheet and anticipated cash flows.investors.hims.com
MarketBeat and other outlets have framed the expanded buyback as a vote of confidence in the long‑term story, especially after a steep pullback from 2025 highs.
Former FDA leader Deb Autor joins as Chief Policy Officer
On the same day, Hims & Hers announced Deb Autor as its first Chief Policy Officer. Autor previously served as Deputy Commissioner for Global Regulatory Operations and Policy at the U.S. FDA and later held senior roles at AstraZeneca.
Her mandate is to lead global policy and regulatory strategy—an important signal as regulators increase scrutiny of telehealth and compounded GLP‑1 therapies. Reuters noted that the hire comes amid a recent FDA warning over allegedly misleading marketing and Hims’ growing reliance on personalized GLP‑1 programs.
GLP‑1 weight-loss engine: powerful growth, real regulatory risk
GLP‑1 medications sit at the center of both the bull and bear cases for HIMS.
Hims’ own GLP‑1 data: strong weight loss, high adherence
In July 2025, Hims & Hers released internal data from 13,458 weight‑loss customers using compounded injectable GLP‑1 medication through its platform.
Headline findings:
- Customers lost an average of 20.9 pounds, or 10.3% of their initial body weight within six months.
- About 75% of patients remained on treatment after six months, compared with dropout rates around 80% at six months reported in some real‑world studies of commercial GLP‑1 use (not directly comparable, but directionally significant).
- Only 10.3% reported side effects, and 4.5% reported intolerable side effects.
- Among those completing a six‑month check‑in, 97% reported improved overall health.
Hims credits its combination of personalized dosing, 24/7 access to clinicians and rich educational content for both the adherence and the outcomes.
Separately, a November eMarketer piece on GLP‑1 “microdoses” highlighted Hims & Hers as one of the telehealth companies offering incremental, compounded doses of semaglutide at fractions of the standard branded dose. This approach aims for fewer side effects and lower cost while staying within FDA provisions that allow customized compounding.EMARKETER
The regulatory cloud
The GLP‑1 strategy is also the core of the regulatory risk:
- In September 2025, the FDA issued warning letters to multiple telehealth companies over their GLP‑1 marketing and compounding practices, including criticism of a Hims & Hers Super Bowl ad that emphasized benefits of GLP‑1 drugs while giving limited attention to side effects.
- The main focus of the letters, as reported by STAT, was on claims that compounded GLP‑1 products are equivalent to FDA‑approved drugs, rather than side‑effect disclosure per se. Companies were told to adjust their messaging.
At the same time, Hims & Hers has said it is in active discussions with Novo Nordisk to offer branded Wegovy injections and a future oral formulation through its platform, which could shift some weight‑loss revenue from compounded to branded products over time.
For now, though, a significant portion of Hims’ growth story leans on compounded GLP‑1s—a segment that could face tighter rules or changing economics if regulators or drugmakers change course.
Wall Street’s view: from “Reduce” to “Hold,” with big dispersion
Analyst opinion on HIMS is unusually split.
A December 1 MarketBeat summary reported that 15 brokerages had assigned Hims & Hers an average rating of “Reduce” (3 Sell, 10 Hold, 2 Buy) with an average 12‑month price target of about $45.27.MarketBeat
On December 5, a fresh MarketBeat note highlighted that Leerink Partners upgraded HIMS to “Strong Buy” from Hold, citing the company’s growth and product momentum. After incorporating this and other recent revisions, MarketBeat now shows:MarketBeat
- 1 Strong Buy
- 2 Buy
- 10 Hold
- 3 Sell
- Average rating: “Hold”
- Average target price: $45.27
StockAnalysis, which tracks 11 analysts, similarly lists an average “Hold” rating and a consensus target of $44.56, implying roughly 11% upside from around $40.StockAnalysis
Within that average are very different narratives:
- Bank of America recently raised its target from $28 to $32 but kept an “underperform” rating, signaling concern about valuation.MarketBeat+1
- Truist Financial cut its target to $37 with a Hold rating.
- BTIG Research maintained a Buy with an $85 target, nearly double the current price.
- Several Seeking Alpha and Motley Fool pieces argue that regulatory fear and recent volatility may have overcorrected the stock, while others still see HIMS as overvalued relative to long‑term growth prospects.
A recent Simply Wall St analysis went further, suggesting that despite a roughly 452% share‑price gain over the last three years, its DCF model still shows Hims & Hers as about 31% undervalued—underscoring just how wide the valuation debate has become.
Big money flows: institutions buying, insiders selling
Fresh 13F data and news coverage show both strong institutional demand and notable insider selling.
From MarketBeat’s December 5 filings coverage:
- Norges Bank initiated a new position of 1,574,009 shares, valued at about $78.46 million, equivalent to roughly 0.7% of the company.
- American Century Companies increased its stake by 23%, buying 42,510 shares to reach a total of 227,575 shares (≈0.10% ownership) worth about $11.35 million.
- Overall, about 63.5% of the float is held by institutional investors and hedge funds.
Insiders, however, have been net sellers:
- MarketBeat highlights insider sales totaling roughly 616,000 shares worth about $32.9 million over the past three months, including a notable sale of 145,000 shares by CFO Oluyemi Okupe.
Insider selling doesn’t automatically mean insiders are bearish—they may be diversifying after a huge multi‑year run—but combined with a high P/E and heavy short interest, it feeds into the “high expectations, handle with care” narrative.
HIMS stock forecast: what the market is really pricing in
Putting today’s news and numbers together, the current HIMS story revolves around a few core questions rather than a single price target.
What the bull case leans on
Supportive analysts and investors tend to emphasize:
- Durable growth: ~49% revenue growth, 21% subscriber growth and rising ARPU suggest the business has real traction beyond hype.
- Business model leverage: Adjusted EBITDA is growing faster than revenue, margins are expanding, and the company is consistently free‑cash‑flow positive.
- Platform expansion: Labs + YourBio + GLP‑1 + international markets (Canada, UK, EU) create multiple growth vectors that could support management’s ambitious $6.5 billion 2030 revenue goal.
- Customer outcomes: Internal GLP‑1 data show strong weight‑loss results and unusually high adherence, which, if sustained, supports long‑run retention and brand equity.
- Balance sheet strength: Hundreds of millions in cash, no dividend drain, and a $250 million buyback authorization give Hims & Hers flexibility to keep investing while returning capital.
What the bear case worries about
Skeptics, including several “Sell”‑rated analysts, focus on:MarketBeat+4Reuters+4STAT+4
- Regulatory overhang: FDA warnings, scrutiny of compounding practices, and evolving rules around GLP‑1s could pressure margins or force changes to key products.
- Dependence on one theme: A significant share of investor enthusiasm (and much of the 2023–25 rerating) hinges on GLP‑1‑driven weight loss; any slowdown or policy shock here would hit sentiment quickly.
- Valuation: A P/E in the mid‑70s and price‑to‑sales around 4x leave little room for error if growth drops below ~30–40% or margins stall.
- Competition: Big pharma, hospital systems, and digital health rivals (including newly launched services from companies like Oddity’s Methodiq) are all racing into similar telehealth niches.
- Volatility and short interest: High beta, a place on “most shorted” lists, and options activity that prices in large swings make HIMS a bumpy ride, not a sleepy compounder.TechStock²+1
Bottom line: a high‑growth telehealth platform at an inflection point
As of December 5, 2025, Hims & Hers is:
- Growing fast,
- Generating real profits and cash flow,
- Aggressively reinvesting in labs, diagnostics and international markets,
- Facing tight regulatory and competitive scrutiny,
- And trading at a valuation that assumes its 2030 vision actually happens.
Wall Street’s average rating of “Hold” and price targets clustered in the mid‑$40s basically encode that split: there is upside if the company continues to execute and navigates GLP‑1 rules smoothly, but the margin for disappointment is thin.StockAnalysis+1
For readers following HIMS, the key variables to watch from here are:
- How quickly Labs + YourBio scale, and whether they move the needle on revenue per user
- The trajectory of GLP‑1 regulation and compounding guidance
- Progress toward the 2026 GLP‑1 revenue goal and 2030 $6.5B target
- The balance between buybacks, insider selling, and ongoing institutional demand
